FDA Scales Back Near-Term Goals For Sentinel Postmarket Data Network

FDA’s Janet Woodcock said the agency has not been able to overcome budgetary restrictions that hamper previously discussed plans to develop the Sentinel postmarket drug safety surveillance system into a much broader national resource.